Difference in the responses after administration of granulocyte colony- stimulating factor in septic patients with relative neutropenia

Journal of Trauma - Injury, Infection and Critical Care

Volumn 48, Issue 5, 2000, Pages 814-825

  Ishikawa, Kazuo ^a   Tanaka, Hiroshi ^a   Nakamori, Yasushi ^a   Hosotsubo, Hideo ^a   Ogura, Hiroshi ^a   Nishino, Masato ^a   Shimazu, Takeshi ^a   Sugimoto, Hisashi ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Granulocyte colony stimulating factor (G CSF); Neutropenia; Sepsis

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOMODULATION; INJURY; LEUKOCYTE COUNT; MALE; NEUTROPENIA; PRIORITY JOURNAL; SEPSIS;

EID: 0033934128     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005373-200005000-00004     Document Type: Conference Paper

References (49)

1. Pinner RW. Trends in infectious disease mortality in the United States. JAMA. 1996;275:189-193.
2. Ishikawa K, Tanaka H, Matsuoka T, et al. Recombinant human granulocyte colony-stimulating factor (rhG-CSF) attenuates inflammatory responses in septic patients with neutropenia. J Trauma. 1998;44:1047-1055.
3. Georges H, Leroy O, Vandenbussche C, et al. Epidemiologic features and prognosis of severe community-acquired pneumococcal pneumonia. Intensive Care Med. 1999;25:198-206.
4. Opal SM, Fisher CJ Jr, Dhainaut J-FA, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med. 1997;25:1115-1124.
5. Cohen J, Carlet J. INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med. 1996;24:1431-1440.
6. Dhainaut J-FA, Tenaillon A, Hemmer M, et al. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: a phase III, randomized, double blind, placebo-controlled, multicenter trial. Crit Care Med. 1998;26:1963-1971.
7. Bone RC. Why sepsis trials fail. JAMA. 1996;276:565-566.
8. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med. 1997;25:1095-1100.
9. Bone RC. Sir Issac Newton, sepsis, and SIRS, CARS. Crit Care Med. 1996;24:1125-1128.
10. Dale DC, Liles WC, Summer WR, et al. Granulocyte colony-stimulating factor -role and relationships in infectious diseases [review]. J Infec Dis. 1995;172:1061-1075.
11. Gross-Weege W, Weiss M, Schneider M, et al. Safety of a low dosage Filgrastim (rhG-CSF) treatment in non-neutropenic surgical intensive care patients with an inflammatory process. Intensive Care Med. 1997;23:16-22.
12. Deboisblanc BP, Mason CM, Anderson J, et al. Phase I safety trial of Filgrastim (r-metHuG-CSF) in non-neutropenic patients with severe community-acquired pneumonia. Respir Med. 1997;91:387-394.
13. Heard SO, Fink MP, Gamelli RL, et al. Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage. Crit Care Med. 1998;26:748-754.
14. Ishikawa K, Tanaka H, Takaoka M, et al. Granulocyte colony-stimulating factor ameliorates life-threatening infections following combined therapy with barbiturates and mild hypothermia in severely head-injured patients. J Trauma. 1999;46:999-1008.
15. Hartung T. Anti-inflammatory effects of granulocyte colony-stimulating factor. Curr Opin Haematol. 1998;5:221-225.
16. Weiss M, Moldawer LL, Schneider M. Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic response syndrome and sepsis. Blood. 1999;93:425-439.
17. Görgen I, Hartung T, Wendel A, et al. Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-α. J Immunol. 1992;149:918-924.
18. Hartung T, Döcke WD, Gantner F, et al. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood. 1995; 85:2482-2489.
19. Roilides E, Walsh TJ, Pizzo PA, et al. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis. 1991;163:579-583.
20. Pajkrt D, Manten A, van der Poll T, et al. Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. Blood. 1997;90:1415-1424.
21. Eissner G, Lindner H, Reisbach G, et al. Differential modulation of IL-1-induced endothelial adhesion molecules and transendothelial migration of granulocytes by G-CSF. Br J Haematol. 1997;97:726-733.
22. Squadrito F, Altavilla D, Squadrito G, et al. The effects of recombinant human granulocyte colony-stimulating factor on vascular dysfunction and splanchnic ischemia-reperfusion injury. Br J Pharmacol. 1997;120:333-339.
23. Philpott NJ, Prue RL, Marsh JC, et al. G-CSF-mobilized CD34 peripheral blood stem cells are significantly less apoptotic than unstimulated peripheral blood CD34 cells: role of G-CSF as a survival factor. Br J Haematol. 1997; 97:146-152.
24. Knaus WA, Zimmerman JE, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-828.
25. Goldfarb MA, Civrej TF, McAslan TC, et al. Tracking respiratory therapy in the trauma patients. Am J Surg. 1975; 129:255-258.
26. Goris RJ, Boekhorst TPA, Nuytinck JKS, et al. Multiple-organ failure: generalized autodestructive inflammation? Arch Surg. 1985;120:1109-1115.
27. Ishikawa K, Tanaka H, Yoshioka T, Sugimoto H. Neutrophil response following administration of recombinant human granulocyte colony-stimulating factor in septic patients with neutropenia. In: Faist E, ed. 4th International Congress on The Immune Consequences of Trauma, Shock and Sepsis Mechanisms and Therapeutic Approaches. Bologna, Italy: Monduzzi Editore; 1997:661-664.
28. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-874.
29. Tanaka H, Ishikawa K, Nishino M, et al. Changes in granulocyte colony-stimulating factor concentration in patients with trauma and sepsis. J Trauma. 1996;40:718-726.
30. Liescke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med. 1992;327:22-35, 99-106.
31. Nagata S, Tsuchiya M, Asano S, et al. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature. 1986;319:415-418.
32. Gabrilove JL, Jakubowski A, Fain K, et al. Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urotherium. J Clin Invest. 1988;82:1454-1461.
33. Moore MA. The clinical use of colony-stimulating factors. Annu Rev Immunol. 1991;9:159-191.
34. Mooney DP, Gamelli RL, O'Reilly M, et al. Recombinant human granulocyte colony-stimulating factor and Pseudomonas burn wound sepsis. Arch Surg. 1988; 123:1353-1357.
35. O'Reilly M, Silver GM, Greenhalgh DG, et al. Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. J Trauma. 1992;33:679-682.
36. Denzlinger C, Holler E, Reisbach C, et al. Granulocyte colony-stimulating factor inhibits the endogenous leukotriene production in tumor patients. Br J Haematol. 1994;86:881-882.
37. Kawakami M, Tsutsumi H, Kumakawa T, et al. Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood. 1990;76:1962-1964.
38. Cebon J, Layton J, Maher D, et al. Endogenous haematopoietic growth factors in neutropenia and infection. Br J Haematol. 1994;86:265-274.
39. Neftel KA, Hauser SP, Müller MR. Inhibition of granulopoiesis in vivo and in vitro by β-lactam antibiotics. J Infec Dis. 1985;152:90-98.
40. Charak BS, Louie R, Malloy B, et al. The effect of amphotericin B, aztreonam, imipenem and cephalosporins on the bone marrow progenitor cell activity. J Antimicrob Chemother. 1991;27:95-104.
41. Lenhoff S, Olofsson T. Effects of immunosuppressive drugs and antibiotics on GM-CSF and G-CSF selection in vitro by monocytes, T lymphocytes and endothelial cells. Br J Haematol. 1996;95:33-38.
42. Gamelli RL, Paxton TP, O'Reilly M. Bone marrow toxicity by silver sulfadiazine. Surg Gynecol Obstet. 1993;177:115-120.
43. Charak BS, Brown EG, Mazumder A. Protective effects of granulocyte colony-stimulating factor against amphotericin B-induced myelosuppression in vitro. Br J Haematol. 1994; 88:693-698.
44. Shoup M, Weisenberger JM, Wang JL, et al. Mechanisms of neutropenia involving myeloid maturation arrest in burn sepsis. Ann Surg. 1998;228:112-122.
45. Elbaz O, Budel LM, Hoogerbrugge H. Tumor necrosis factor downregulates granulocyte colony-stimulating factor receptor expression on human acute myeloid leukemia cells and granulocytes. J Clin Invest. 1991;87:838-841.
46. Imashuku S, Ikushima S, Esumi N, et al. Serum levels of interferon-gamma, cytotoxic factor and soluble interleukin-2 receptor in childhood hemophagocytic syndromes. Leuk Lymphoma. 1991;3:287-292.
47. Ferrara JLM. Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immunol. 1993;5:794-799.
48. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295-304.
49. Pan L, Demolte J, Jalonen CK, et al. Pretreatment of donor mice with granulocyte colony-stimulating factor polarized donor T lymphocytes toward type-2 cytokine and reduces severity of experimental graft-versus-host disease. Blood. 1995;86:4422-4429.